Vitalis Therapeutics is a physician-researcher-founded pharmaceutical company developing non-opioid therapies for acute post-operative pain, with an initial focus on oral ketamine for patients recovering from total knee replacement. Its lead candidate, VS-1, is in planning for a Phase 2a clinical trial and is designed to reduce opioid use while supporting earlier mobility and recovery at home. The company works with orthopedic surgeons and uses a compounding-pharmacy pathway to pursue early access for interested patients.
MAXONA Pharmaceuticals, IncMAXONA Pharmaceuticals is a clinical-stage drug developer advancing MAX-001, a patent-protected, non-opioid and non-NSAID treatment candidate for acute and chronic pain. Founded by President and CEO Shawn Fatholahi, the company draws on a leadership team with deep experience in neuroscience, formulation, clinical development and regulatory affairs. MAX-001 has completed its IND-enabling studies and Phase I trials, with Phase II development expected to be completed in 2026.MALVERN, PA
MindLabFounded by pharmaceutical and legal executive Larry Raoul James, MindLab is a pain-therapy company developing treatments intended to deliver morphine-level relief with less risk of abuse-related harm. Its work centers on MLB-001, a proposed morphine replacement for patients who need effective pain control without the consequences associated with conventional opioid therapy.New York, NY
Formae, IncFormae, Inc. develops CyborGel®, an investigational synthetic hydrogel cartilage implant system for minimally invasive knee resurfacing in progressive and post-traumatic osteoarthritis. Founded by orthopedic surgeon Kevin Mansmann, M.D., the company brings together medical, engineering, additive-manufacturing and entrepreneurial experience built through more than 25 years of research and development. CyborGel has received FDA Breakthrough Device Designation and remains limited to preclinical use while regulatory submissions and medical trials continue.DEVON, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA